Advanced Genomics Platform for Next-Generation Cancer Therapies



Investor Presentation December 2019

Forward-Looking Statements

This presentation and the accompanying oral presentation contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this presentation, including statements as to future results of operations, financial condition, business strategy, plans, and objectives of management for future operations of Personalis Inc. ("Personalis" or the "Company"), future market sizes, potential success of personalized cancer therapies and other drugs, the developing and potential competitive landscape for genomic sequencing platforms, and others, are forward-looking statements. These statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements are subject to risks and uncertainties, including those discussed in Personalis' filings with the Securities and Exchange Commission ("SEC"), including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic report on Form 10-Q and subsequent filings and in the documents incorporated by reference therein.

In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would," or the negative of these words or other similar terms or expressions. These statements are only predictions. Personalis has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its business, financial condition and results of operations. Also, these forward-looking statements represent the Company's estimates and assumptions only as of the date of this presentation. The Company assumes no obligation to update any forward-looking statements after the date of this presentation.

This presentation also contains estimates and information concerning the Company's industry and business, including estimated market size, projected growth rates of the markets in which Personalis participates and the prevalence of certain medical conditions. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. The Company has not independently verified the statistical and other industry data generated by independent parties and contained in this presentation and, accordingly, it cannot guarantee their accuracy or completeness. In addition, projections, assumptions and estimates of its future performance and the future performance of the industries in which it operates are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by Personalis.

The trademarks included in this presentation are the property of the owners thereof and are used for reference purposes only.




Cancer drug development is increasingly about data...

... and Personalis is positioned to be a key part of that ecosystem



Personalis Provides Proprietary Genomic Information to Customers


Efforts to develop better cancer drugs increase demand for genomic information






Personalis is Transforming the Development of Next-Generation Cancer Therapies

Providing biopharma with more comprehensive molecular data about patient tumors






Biopharma Customers are Using Molecular Data to Address a Large Opportunity





Personalis is Purpose-Built for Biopharma

Our comprehensive solution represents the next step in biopharmaceutical research





Platform Leadership Over Generations of Innovation

ACE ImmunoID

I-O Focused First Gen Platform Technology

Combined exome and transcriptome sequencing using ACE technology

Increased variant specificity and sensitivity

Launched November 2016

Launched in 2013

performance

~20,000 genes

ACE Exome Technology

Superior sequencing performance for

Genome Medicine and Nature Review

publications demonstrating leading exome

ACE ImmunoID for Personalized Cancer Therapy

ACF ImmunoID

for Biomarkers

identification

Platform extended for biomarker

ImmunogenomicsID for tumor and microenvironment

Platform extended for personalized therapy customers

NeoantigenID

Improved turn around time

Device master file with FDA

ImmunoID NeXT


Universal Cancer Immunogenomics Platform Complete picture of cancer and immune genomics from a single sample

Applicable across I-O, targeted and personalized therapies

Announced in November 2018 Launched in 2019



Diagnostic Panels Utilize Human Tissue But Aren't Comprehensive





Proprietary Platform Maximizes Insights from a Single Sample

Patient Tumor Samples Are Often Extremely Limited



Traditional Process Multiple Samples | Multiple Vendors | Multiple Assays


- Targeted Therapy Panel (often 50 to 500 genes)
- Neoantigen Identification from Exome
- Expression Data from Array
- TCR / Immune Cell Repertoire
- MSI-Testing
- Oncoviral Testing
- Remaining Sample, if any, Sent to Discovery and Translational Teams
 - HLA-Testing



Comprehensive Data with a Limited Sample Higher Success Rate and Lower Costs




Patching Together a Profiling Solution with Multiple Offerings is Challenging...






...Leading to an Incomplete Picture of Cancer and Low Rates of Success



Viewing a singular aspect of tumor biology limits conclusions




5.1%

The likelihood of FDA approval from Phase I clinical trial for oncology developmental candidates¹



Proprietary Assay and Analytics for the Many Elements of Tumor Biology


ImmunoID NeXT



Personalis customers can select features of the platform to meet their particular needs. An * denotes next-generation feature in development.



Differentiated Analytics Driven by Proprietary Content




Proprietary Sequencing Methods Achieve Superior Coverage and Gene Finishing

Coverage, depth and accuracy are key in oncology

Superior sequencing performance¹


Coverage of difficult-to-sequence gene regions



🙌 Personalis[.]

Comprehensiveness Allows Customers to Understand Why Patients Respond

At an average cost of ~\$60,000 per patient in oncology clinical trials,¹ understanding why patients do or don't respond is critical




Developing Liquid Biopsy Capabilities to Complement Tissue Sample Insights


Purpose-built for pharma clinical research

~ 20,000 genes in both tissue and liquid biopsy versions

Tissue is critical for immune cells and RNA, but cfDNA complements with new insights and serial time points



Mutations Found in Tissue Samples and cfDNA are Important for Drug Development



Numbers indicate variants detected in the tumor only, plasma only, or in both.



Our Customer Applications – Biopharma Companies



Immunotherapies

Platform provides comprehensive insights on tumor **and** immune biology



Targeted Therapies

Patient's genomic and immune profile critical for pharma R&D

\sim (

Personalized Cancer Therapies

Information we provide can be used to design **individually tailored** therapies



U.S. VA Million Veteran Program

National research program to learn how genes, lifestyle, and military exposures affect health and illness.

- Enrolling veterans nationwide at a rate of approximately 100,000 a year
- 800,000 veterans enrolled in program to-date



Personalis is the whole genome sequencing provider to U.S. VA Million Veteran Program

Long-term partner Working together since 2012 with approximately \$145M of orders to date

> Significant customer offering stability and scale 2018A Revenue of \$18.6M 3Q'19 Revenue of \$12.9M

> > Personalis is currently contracted to deliver ~100,000 samples

Awards to date expected to be revenue into early 2021 (\$82.5M backlog)¹



MILLION VETERAN PROGRAM


DISCOVERY * INNOVATION * ADVANCEMENT

Offers key experience as cancer analysis eventually moves to whole genome

🙌 Personalis[.]

1. As of September 30, 2019, the remaining performance obligations under contracts with the VA MVP for which revenues are expected to be recognized over a period of more than one year was \$82.5 million. Management expects to recognize such revenues over an 18 month period.


Market Opportunity Grows as Use Increases





Personalis Provides Information that May Be Used in Personalized Cancer Therapies

- We believe we are working with the majority of companies developing neoantigen-targeted personalized cancer therapies
- Involved in first-in-human clinical trials
- Addresses key challenges with unique technology
 - Seeing more neoantigens
 - Predicting which neoantigens will be immunogenic
 - Comprehensive immuno-genomic biomarkers
- Rapid turnaround time
- >95% success rate with samples¹
- Personalis' FDA Device Master File enables long-term success with our customers
- Potential to derive revenue in connection with the sale of personalized therapeutics developed using our platform



What's Next?

Develop NeXT as a Clinical Diagnostic Platform

- Clinical diagnostic test built for advanced immuno-therapies
- Genes related to classic targeted therapies boosted to > 1,000x coverage
- Initial clinical interpretation builds on three years of experience with our earlier targeted-therapy panelbased test
- Platform to work with pharma and collaborators to build clinical utility evidence with advanced therapies
- Long-term upside as the diagnostic platform of next-generation IO


Personalis®				C			p
ACE Can	cerPlus Tes	st				ACCR	EDITED.
Increasingly, oncologie	its and pathologists are u	ilizing information on		es of Clinica Raso Subs	Importance itutions, Inde	le and Gone	Euclone
	solid tumors, such as lune		Analyzed to	CEEN	HEA	N/C	PUSIONS
	to help guide and optimiz onalis ACE CancerPlus Te		ACTI	CHEM	HEAS	MYCN	8148
	curate next generation se		AKT2	CREBEP	IDH1	MYD68	FHOA
solution for solid turno			AKT2	CRUF2	1042	M79-RD	8m
			ALK	CRECI	ISPIR	NFI	ROSI
Clinical Reports			APC AR	CSFIR	ILER JAKI	NP2 NPE2L2	RPM
Personalis ACE Cance	Plus Test is a comprehen	sive genomic testing	ARAF	DD#2	JAK2	NPERA	RUNKIT
		t on the genetic alterations	ARID/A	DEK	TWG	N8024	SF281
	of medical importance. V		ASRL1	DNMT3A	KDR	NOTCHI	SMAD2
	vide high accuracy, clinica its to identify base substit	i grade next generation utions, insertions/deletions,	ATM	DONE	Karrsta	NOTCH2	SMAD4
copy number alteration		addina, inter dona deredona,	A79	87184	KOTT	NPME	SMARCA
	ed to clinicians in hard co	ov and PDF format.	AURA	ER202	KMT2A KR45	NRAS NTRV3	SMO
The ACE CancerPlus T	est report describes clinic	ally important genomic	AURC	PREDA	1306	NTEK2	54%
alterations and potenti	ally relevant therapies an	d clinical trials.	BAP1	893	MAP2K1	NTEG	ST462
			BCL2	EEEE	MAP2K2	NUF214	STKH
What Makes Out	Test Unique		BCOR	ES#1	MAP264	PDCD1	SYK
The Personalis ACE C	ancerPlus Test goes beyo	nd typical cancer genomics	BCR R	ETVI	MAPSIC	POOPEA	TERT
tests in a few key area	6:		BRAP	ETV4	MAPICI MAPICI	POSPIE	1612
	ethods for Improving seq		BRCA2	ETVS	MCL1	PRICA	TMPRSS
	fficult to sequence region		gTK .	EWSRI	MDH2	PHOCE	TNESEL
	n other cancer panel tests		CBFB	820+2	MDM4	PK3CD	TPS3
	NA and RNA from the sam of gene fusions over a bro	e sample to enable robust	OCND1	FEXM/7	NECOM	PIKICG	TSC1
identitication	of gene tusions over a bri	oad number of genes.	COND2	FGFR1	MED12	PIKOR1	1902
			CONDO	POFR2	MENI	PML	U2AF1
	erformance Specifical	tions	COHI	FSFR4	MIP	PTCHI	VEOPE
Regulation Required	Yes		CD#3	RCN	MOCL1	PTEN	VHL
Specimen Types Realons Analyzed	FFPE, Fresh Frazen, 220% Coding regions of 181 gen		CDH2	R/1	MDH	PTPM1	wn
Type of Sequencing	DNA and RNA using illumi		CDK4	PLT3	MULTIO MULTI	R4035	XPOI 201582
Typical Median Depth	UNA and KNA Using illumi	na NGS	CDRM	PLT4	MUUT3	RAD21	29(542
Terraround Time	-3 www.itt		CDKNB	GNA/I	MSH2	RARA	
Specifications			CDRN2A	GNAD	MSHG	REI	
Sensibyby	Rase Substitutions	(AF* 25%) >99%	CO#N28	GNAS	MTOR	RONIS	
	Indels	(AF ≥10%) >99%					
	Copy Number Alterations	96% for tumor content	41 Cancer C	enes Analyz	ed for Copy P	Kumber Aiter	
		210%	ABUI	CDK4 CDKNDA	FOFRA	MET	POOPINA
	Gene Rusions	×95%	AKT2	CORNER	JACI	MUTZ	PIERLA
Specificity (PPV**)	Base Substitutions	(AF 25%) 99%	ALK	DOFR	KOT	N942	RAD21
	Indels	(AF 210%) >99%	AUEKA	81882	1345	MIC	FIB1
WF = Allele Fraction			BCR	68683	MAPE3	NO24	867
*PPV = Positive Precicitive Va	*PPV = Positive Predictive Value			FGFRI DSER2	MCL1 MCM2	NTRR3	ROSI
			CDHI	PGPR2	MDH2	NUP214	SMAC4
					Dec		
	1330 O'Brien Drive m +1-650-752-134	i Menio Park, CA 94025 9	5	W	Pioneering		
		not ACE Policent ACE Convent and					920.7

Build a Tumor Immuno-Genomics Database Personalis "Genomics Engine" 🙀 Personalis[®] for Personalized Cancer Vaccine & Adoptive Cell Therapy Development Immuno-genomics DB 100's-1.000's of patients Cancer Cells and Immune Cells Adaptive **and** Innate Immune Systems Human **and** Oncoviral Genomics Personalis Universal 20,000 Genes Biomarker Platform for all ACE Exome and Transcriptome Immuno-oncology and Neoantigens & Escape Combination Clinical Trials 10.000's of patients Mechanisms Exome-scale TMB HLA & Antigen Presenting Machinery Microsatellite Instability (MSI) Cancer Drivers Personalis Universal Targeted Therapy Targets **Diagnostic for Cancer** Patients (IO, TT, PCV, P-ACT) Data from 100,000's of patients 100,000's of patients

Novel Cancer Therapeutic Insights Drive Therapeutic Development



Strong Financial Profile and Historical Growth





1. Represents customer deposits for the prepayment of a portion of services that the customer expects to order from us. If a customer that has prepaid us for future services cancels its contract with us or reduces the level of services that it expects to receive, we would generally be required to repay that customer's deposit

Experienced Leadership Team

John West President, Chief Executive Officer & Director	Richard Chen, M.D., M.S. Chief Scientific Officer	Clinton Musil Chief Business Officer	Aaron Tachibana Chief Financial Officer
illumina" Sole 🛵 🍋 Biosystems	INGENIIITY [®] Stanford		
MANAGEMENT TEAM	SYSTEM 5 Medicine	BIOSCIENCES —	Semiconductor Corporation
Christian Haudenschild, Ph.D.	VP Operations	illumına [°] Solexa	LYNX
Michael Fitzpatrick	VP Sales	AB applied biosystems	
Carol Tillis	VP Finance and Administration		
Rena McClory, Ph.D.	VP Marketing	illumına" Agilent	RainDance Reinstructure
Lloyd Hsu	VP Software Engineering		Technologies
Xavier Paliard, PharmD, Ph.D.	VP Immunology and R&D		MERCK 🕖 NOVARTIS
NON-EMPLOYEE DIRECTORS			
Jonathan MacQuitty, Ph.D.	Chairman of the Board	Lightspeed 🤄 Forty Seven	
Patrick Balthrop	Director	Luminex Oxford	
A. Blaine Bowman	Director	illumına 🗊 DIONEX	
Alan Colowick, M.D.	Director	SOFINNOVA AMGEN	Celgene Human Longevity.
Karin Eastham	Director	illumına" 🗸 veracyte. NEKT	_
Kenneth Ludlum	Director	CareDx natus	
Paul Ricci	Director	Lightspeed WARBURG PIN	

🙌 Personalis[®]

Operational Excellence

100,000+ human samples of anticipated current capacity annually

Significant focus on process development

including with laboratory automation, to drive margin expansion

Differentiated QMS and Regulatory Credentials CLIA / CAP, NY State¹ & FDA² - all at exome scale


Headquartered in Menlo Park, CA

Over 170 employees

Specialized sales force fosters deep relationships

Intellectual Property Protections including 10 issued U.S. and foreign patents

Growth of Personalis' Sequencing Capacity Sequencing capacity at Q1





Key Upcoming Milestones

Planned new product launches

Growing proprietary content to drive further product differentiation

Customer & collaboration results to increasingly demonstrate clinical utility

- Expect to receive orders for ImmunoID NeXT in 2019 with revenue in 2020
- Clinical diagnostic based on ImmunoID NeXT, for pharma & collaborations
- Exome-scale cell-free DNA liquid biopsy for neoantigens to be launched in 2020

- Mass spec data for HLA-peptide binding
- Immuno-genomics database reaches scale to benefit biopharma customers
- Expect to demonstrate neoantigen and tumor escape dynamics using exomescale cell free DNA assay
- Potential for use as companion diagnostic to better understand a patient's therapeutic response to checkpoint inhibitors
- Potential for personalized therapy customers to demonstrate efficacy using adoptive cell therapies & cancer vaccines



Cancer Drug Development is Increasingly About Data...

... and Personalis is positioned to be a key part of that ecosystem



"Genomics Engine" for Next-Generation Cancer Therapies

Covers all ~20,000 human genes and the immune system from a single tumor tissue sample

Purpose-built for biopharma to help better understand cancer

Complementary liquid biopsy assay with broad 20,000-gene coverage in development



Positioned to Capitalize on Major Trends in Oncology R&D

Molecular data from cancer patients is increasingly used to develop therapeutics

Current molecular profiling panels only cover ~50-500 genes and miss critical tumor and immune biology

Immunotherapies, targeted therapies and personalized cancer medicines require more comprehensive genomic profiling



Potential to Unlock Value in Massive Markets

\$5Bn estimated initial addressable market for biopharmaceutical customer R&D

\$14Bn estimated addressable future market for diagnostic opportunity

\$40Bn estimated addressable future market based on commercialization of personalized therapeutics



Strong Financial Profile and Historical Growth

Strong historical revenue growth

Initial commercial model not subject to any reimbursement from payors

More than 45 biopharmaceutical customers since inception

VA MVP is a significant customer offering scale and stability

Highly targeted enterprise sales model

Endnotes

Page 5:

1. Number of patients and clinical trials are based on data from the U.S. National Library of Medicine, ClinicalTrials.gov, January 2019; assumes that patients in such clinical trials will receive one tumor biopsy test and three liquid biopsy tests over the course of a clinical trial, and the cost of tumor and liquid biopsy tests will be \$5,000 and \$7,000 on average, respectively

Page 6:

- 1. IQVIA MIDAS; IQVIA Institute, Dec 2017
- 2. Tufts CSDD "Personalized Medicine is Gaining Traction, but Faces Multiple Challenges" (14-May-2015)
- 3. Biotechnology Innovation Organization (BIO), Biomedtracker, and Amplion "Clinical Development Success Rates 2006-2015" (Jun-2016)

Page 12:

1. Biotechnology Innovation Organization (BIO), Biomedtracker, and Amplion "Clinical Development Success Rates 2006-2015" (Jun-2016)

Page 15:

1. Patwardhan et al. Genome Med. 2015

Page 16:

1. Biopharmaceutical Industry-Sponsored Clinical Trials: Impact on State Economies, 2013

Page 21:

1. As of December 31, 2018, the remaining performance obligations under contracts for which revenues are expected to be recognized over a period of more than one year is \$73 million. Management expects to recognize such revenues over a three-year period.

Page 22:

- 1. Number of patients and clinical trials are based on data from the U.S. National Library of Medicine, ClinicalTrials.gov, January 2019; assumes that patients in such clinical trials will receive one tumor biopsy test and three liquid biopsy tests over the course of a clinical trial, and the cost of tumor and liquid biopsy tests will be \$5,000 and \$7,000 on average, respectively
- 2. Based on a combination of data derived from the American Cancer Society, Cancer Facts and Figures 2018, 2018, American Cancer Society, Cancer Facts and Figures 2019, 2019, and a review article from the European Journal of Cancer, Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018, August 9, 2018. We assume that pre-diagnosis cancer patients will receive one oncology clinical diagnostic test to inform their treatment strategy or to identify clinical trial enrollment opportunities, and the cost per test will be \$3,000 on average, which we believe is in line with current cancer panels.
- 3. Based on a combination of data derived from Public Health Faculty Publications, SEER Cancer Statistics Review, 1975-2015 (only data relating to cancer cases diagnosed and the respective stage of disease upon diagnosis from 2008 to 2014 was used for our purposes), American Cancer Society, Cancer Facts and Figures 2018, 2018, American Cancer Society, Cancer Facts and Figures 2018, 2018, American Cancer Society, Cancer Facts and Figures 2018, 2018, American Cancer Society, Cancer Facts and Figures 2019, 2019, and a review article from the European Journal of Cancer, Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018, August 9, 2018. We assume that personalized cancer therapy patients will receive one tumor biopsy test and three liquid biopsy tests over the course of a clinical trial or treatment, with the average cost per test being the same as is outlined above in the United States and \$3,000 and \$4,200 on average per test, respectively, in the European Union.

Page 23:

1. For prospectively collected FFPE samples with our personalized therapy partners, we achieve a greater than 95% success rate for obtaining high-quality data from tumor samples received from personalized cancer therapy customers due to our optimized nucleic acid extraction protocols

Page 27:

- 1. We maintain a current license with the New York State Department of Health for our laboratory
- 2. We have filed a Device Master File with the FDA